Fast and accurate simulations of transmission-line metamaterials using transmission-matrix method

Recently, two-dimensional (2D) periodically L and C loaded transmission-line (TL) networks have been applied to represent metamaterials. The commercial Agilent's Advanced Design System (ADS) is a commonly-used tool to simulate the TL metamaterials. However, it takes a lot of time to set up the TL network and perform numerical simulations using ADS, making the metamaterial analysis inefficient, especially for large-scale TL networks. In this paper, we propose transmission-matrix method (TMM) to simulate and analyze the TL-network metamaterials efficiently. Compared to the ADS commercial software, TMM provides nearly the same simulation results for the same networks. However, the model-process and simulation time has been greatly reduced. The proposed TMM can serve as an efficient tool to study the TL-network metamaterials.Comment: 15 pages, 13 figure

Waveguide-plasmon polaritons enhance transverse magneto-optical Kerr effect

Magneto-optical effects in ferrimagnetic or ferromagnetic materials are usually too weak for potential applications. The transverse magneto-optical Kerr effect (TMOKE) in ferromagnetic films is typically on the order of 0.1%. Here, we demonstrate experimentally the enhancement of TMOKE due to the interaction of particle plasmons in gold nanowires with a photonic waveguide consisting of magneto- optical material, where hybrid waveguide-plasmon polaritons are excited. We achieve a large TMOKE that modulates the transmitted light intensity by 1.5%, accompanied by high transparency of the system. Our concept may lead to novel devices of miniaturized photonic circuits and switches, which are controllable by an external magnetic field

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

Comprehensive molecular characterization of urothelial bladder carcinoma

Urothelial carcinoma of the bladder is a common malignancy that causes approximately 150,000 deaths per year worldwide. So far, no molecularly targeted agents have been approved for treatment of the disease. As part of The Cancer Genome Atlas project, we report here an integrated analysis of 131 urothelial carcinomasto provide a comprehensive landscape of molecular alterations. There were statistically significant recurrent mutations in 32 genes, including multiple genes involved in cell-cycle regulation, chromatin regulation, and kinase signalling pathways, as well as 9 genes not previously reported as significantly mutated in any cancer. RNA sequencing revealed four expression subtypes, two of which (papillary-like and basal/squamous-like) were also evident in microRNA sequencing and protein data. Whole-genome and RNA sequencing identified recurrent in-frame activating FGFR3-TACC3 fusions and expression or integration of several viruses (including HPV16) that are associated with gene inactivation. Our analyses identified potential therapeutic targets in 69% of the tumours, including 42% with targets in the phosphatidylinositol-3-OH kinase/AKT/mTOR pathway and 45% with targets (including ERBB2) in the RTK/MAPK pathway. Chromatin regulatory genes were more frequently mutated in urothelial carcinoma than in any other common cancer studied so far, indicating the future possibility of targeted therapy for chromatin abnormalitiesclose27